The evolution of Tamiflu synthesis, 20 years on : Advent of enabling technologies the last piece of the puzzle?
© 2020 Elsevier Ltd. All rights reserved..
Influenza is a serious respiratory disease responsible for significant morbidity and mortality due to both annual epidemics and pandemics; its treatment involves the use of neuraminidase inhibitors. (-)-Oseltamivir phosphate (Tamiflu) approved in 1999, is one of the most potent oral anti-influenza neuraminidase inhibitors. Consequently, more than 70 Tamiflu synthetic procedures have been developed to date. Herein, we highlight the evolution of Tamiflu synthesis since its discovery over 20 years ago in the quest for a truly efficient, safe, cost-effective and environmentally benign synthetic procedure. We have selected a few representative routes to give a clear account of the past, present and the future with the advent of enabling technologies.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
---|---|
Enthalten in: |
Tetrahedron - 76(2020), 37 vom: 11. Sept., Seite 131440 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Sagandira, Cloudius R [VerfasserIn] |
---|
Links: |
---|
Themen: |
Enabling technologies |
---|
Anmerkungen: |
Date Revised 02.03.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1016/j.tet.2020.131440 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM314130608 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM314130608 | ||
003 | DE-627 | ||
005 | 20231225152056.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.tet.2020.131440 |2 doi | |
028 | 5 | 2 | |a pubmed24n1047.xml |
035 | |a (DE-627)NLM314130608 | ||
035 | |a (NLM)32839628 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Sagandira, Cloudius R |e verfasserin |4 aut | |
245 | 1 | 4 | |a The evolution of Tamiflu synthesis, 20 years on |b Advent of enabling technologies the last piece of the puzzle? |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 02.03.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a © 2020 Elsevier Ltd. All rights reserved. | ||
520 | |a Influenza is a serious respiratory disease responsible for significant morbidity and mortality due to both annual epidemics and pandemics; its treatment involves the use of neuraminidase inhibitors. (-)-Oseltamivir phosphate (Tamiflu) approved in 1999, is one of the most potent oral anti-influenza neuraminidase inhibitors. Consequently, more than 70 Tamiflu synthetic procedures have been developed to date. Herein, we highlight the evolution of Tamiflu synthesis since its discovery over 20 years ago in the quest for a truly efficient, safe, cost-effective and environmentally benign synthetic procedure. We have selected a few representative routes to give a clear account of the past, present and the future with the advent of enabling technologies | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Enabling technologies | |
650 | 4 | |a Evolution | |
650 | 4 | |a Influenza | |
650 | 4 | |a Tamiflu synthesis | |
700 | 1 | |a Mathe, Francis M |e verfasserin |4 aut | |
700 | 1 | |a Guyo, Upenyu |e verfasserin |4 aut | |
700 | 1 | |a Watts, Paul |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Tetrahedron |d 1963 |g 76(2020), 37 vom: 11. Sept., Seite 131440 |w (DE-627)NLM041534816 |x 0040-4020 |7 nnns |
773 | 1 | 8 | |g volume:76 |g year:2020 |g number:37 |g day:11 |g month:09 |g pages:131440 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tet.2020.131440 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 76 |j 2020 |e 37 |b 11 |c 09 |h 131440 |